The effect of concomitant COPD on obstructive sleep apnea syndrome severity and sleep structure Source: Annual Congress 2011 - Obstructive sleep apnoea as a comorbidity Year: 2011
Impact of sleep onset on hemodynamic parameters in obese patients with or without obstructive sleep apnea Source: International Congress 2017 – New pathophysiological insights: intermittent hypoxia, cardiopulmonary function and biomarkers Year: 2017
The effect of CPAP treatment on Galectin-3 level in patients with severe obstructive sleep apnea Source: International Congress 2018 – Cardiovascular and metabolic consequences of sleep-disordered breathing Year: 2018
Fibrinogen level in patients with severe obstructive sleep apnoea syndrome (OSAS). Effect of n-CPAP therapy Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
Prolonged symptoms and sleep quality after hospitalization for covid-19 in patients with obstructive sleep apnoea Source: Virtual Congress 2021 – Different treatment modalities and impact of comorbidities on sleep disordered breathing Year: 2021
Effect of nCPAP-therapy to depressive symptoms in patients with obstructive sleep apnea Source: Annual Congress 2010 - Sleep disorders: neurology, smoking and daytime sleepiness Year: 2010
Eficacy of the treatment with CPAP in patients with chronic heart failure and sleep apnoea Source: Eur Respir J 2004; 24: Suppl. 48, 564s Year: 2004
The influence of long-term CPAP therapy on metabolic variables in obstructive sleep apnea patients Source: International Congress 2018 – Cardiovascular and metabolic consequences of sleep-disordered breathing Year: 2018
Effects of nCPAP treatment on quality of life of patients with obstructive sleep apnoea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 410s Year: 2006
Effect of multiple-dose treatment with daridorexant on nighttime respiratory function in patients with mild and moderate obstructive sleep apnea (OSA) Source: Virtual Congress 2020 – Treatment of obstructive sleep apnoea and its effects Year: 2020
Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities Source: Eur Respir J, 51 (6) 1800601; 10.1183/13993003.00601-2018 Year: 2018
Impact of CPAP-therapy on cardiac structure and function in patients with obstructive sleep apnea syndrome and coprevalent arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 817s Year: 2006
Unrecognised systemic hypertension in patients with obstructive sleep apnoea Source: Eur Respir J 2006; 28: Suppl. 50, 643s Year: 2006
Effects of treatments with nCPAP on cerebral blood flow velocity in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2009 - Assessment and therapeutical interventions in obstructive sleep apnoea Year: 2009
Effects of CPAP treatment on physical fitness in patients with obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 97s Year: 2003
Predictors of residual sleepiness in adequately treated obstructive sleep apnoea patients Source: Annual Congress 2009 - Cardiovascular complications in obstructive sleep apnoea Year: 2009
Cardiovascular regulation effects of CPAP therapy in obstructive sleep apnea patients with and without hypertension during daytime Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012
Is the daily duration of nasal CPAP ventilation the main determinant of improvement of blood gases in OSAS (obstructive sleep apnoea syndrome) patients? Source: Eur Respir J 2001; 18: Suppl. 33, 390s Year: 2001
Efficacy of continuous positive airway pressure in treatment of patients with bradyarrhythmias associated with obstructive sleep apnoea syndrome Source: Annual Congress 2006 - Cardiovascular consequences of obstructive sleep apnoea Year: 2006
Effect of stable sleep on hemodynamic parameters in patients with obstructive sleep apneas Source: Annual Congress 2010 - Complex sleep apnoea, opioids, adaptive servoventilation, bilateral positive airway pressure and continuous positive airway pressure Year: 2010